Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: A meta-analysis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  De Vries, Folgerdiena M ^a   Kolthof, Johan ^a   Postma, Maarten J ^a   Denig, Petra ^b   Hak, Eelko ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DIABETES COMPLICATIONS; RISK; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DIABETES COMPLICATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84910683956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111247     Document Type: Article

References (40)

1. World Health organisation (2012) Global Health Observatory 2012. Available: http://www.who.int/gho/mortality-burden-disease/en/. Accessed 2014 Sept 8.
2. American Heart Association (2013) Cardiovascular disease and diabetes [online]. Available: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes-UCM-313865-Article.jsp. Accessed 2014 Sept 8.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143.
4. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30:162-172.
5. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117-125.
6. Costa J, Borges M, David C, Vaz Carneiro A (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332:1115-1124.
7. Knopp RH, D'Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29:1478-1485.
8. Chang YH, Hsieh MC, Wang CY, Lin KC, Lee YJ (2013) Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients - A systematic review and meta-analysis. Rev Diabet Stud 10:157-170.
9. Warner C, Krane V, Marz W, Olschewski M, Mann JF, et al. (2005) Dialysis Study I. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248.
10. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376:1670-1681.
11. Heintjes EM, Penning-van Beest FJA, Plat AW, Meerding WJ, Webb K, et al. (2012) Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy 32:631-641.
12. Sidorenkov G, Haaijer-Ruskamp FM, De Zeeuw D, Denig P (2011) A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness. PLoS One 6:e24278.
13. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA 292:1307-1316.
14. Ahmed S, Cannon CP, Murphy SA, Braunwald E (2006) Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. European Heart Journal 27:2323-2329.
15. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376:1658-1669.
16. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J, et al. (2006) Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The treating to new targets (TNT) study. Diabetes Care 29:1220-1226.
17. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423.
18. Smith MEB, Lee NJ, Haney E, Carson S (2009) Drug class review: Hmg-coa reductase inhibitors (statins) and fixed-dose combination products containing a statin: Final report update 5. Portland (OR).
19. Weng TC, Yang YH, Lin SJ, Tai SH (2010) A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35:139-151.
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12.
21. Cook RJ, Sackett D (1995) The number needed to treat: a clinically useful measure of treatment. BMJ 310:452-454.
22. The Cochrane Collaboration (2011) Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
23. Scholten RJ, Kostense PJ, Assendelften WJ, Bouter LM (1999) De praktijk van systematische reviews. IV. Het combineren van de resultaten van afzonderlijke onderzoeken. [In Dutch] Ned Tijdschr Geneeskd 143:786-791.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557-560.
25. Pyrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620.
26. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98:2513-2519.
27. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016.
28. Keech A, Colquhoun D, Best J, Kirby A, Simes LA, et al. (2003) Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26:2713-2721.
29. Post Coronary Artery Bypass Graft Trial Investigators (1997) The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336:153-162.
30. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) (2000) Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1:810-820.
31. Serruys PW, De Feyter R, Macaya C, Kokott N, Puel J, et al. (2002) Fluvastatin for prevention of cardiac events following succesfull first percutaneous coronary intervention: a randomized controlled trial. JAMA 287:3215-3222.
32. Cardiovasculair risicomanagement (2012) (Tweede herziening) [In Dutch] Huisarts Wet 55(1):14-28.
33. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635-1701.
34. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 36:227-229.
35. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, et al. (2013) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation; 129 [suppl 2]: S1-S45.
36. Armitage J (2007) The safety of statins in clinical practice. Lancet 370:1781-1790.
37. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, et al. (2007) Metaanalysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29:253-260.
38. Newman C, Tsai J, Szarek M, Luo D, Gibson E (2006) Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14, 236 patients. Am J Cardiol 97:61-67.
39. Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, et al. (2013) Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes 6:315-322.
40. Fintel D, Joyce A, Mackell J, Graff J, Kuntze E, et al. (2007) Reduced mortality rates after intensive statin therapy in managed-care patients. Value Health 10:161-169.